Floatz logo

Taladegib

Solid Tumors With PTCH1 Loss-of-function Mutations

Endeavor Biomedicines, Inc.Small moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Solid Tumors With PTCH1 Loss-of-function Mutations cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Taladegib is also rated in:

idiopathic pulmonary fibrosisDormant
CCC
Indicative ·
55 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →